Signet Therapeutics announces IND approval by the FDA for world’s first targeted therapy for DGC Read more
US body Clinical and Laboratory Standards Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime- WCK 5222) Read more
Asthma inhaler price cap in US may help pharma companies to secure more loyal customer base: GlobalData Read more